SAP at Globe Series: Procurement to Build Back Better

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of Myoung Cha as Director

Effective June 15, 2022, the Board of Directors (the “Board”) of Tandem Diabetes
Care, Inc.
(the “Company”) elected Myoung Cha, age 45, to serve as a Class III
director on the Board, with a term that expires at the Annual Meeting of
Stockholders of the Company to be held in 2023 or until his earlier resignation
or removal. The Board has approved Mr. Cha’s appointment to the Compensation
Committee. The Board has affirmatively determined that Mr. Cha qualifies as an
“independent director” under the Nasdaq Listing Rules.

Mr. Cha has more than 17 years of global experience across the healthcare value
chain. Mr. Cha currently serves as President and Chief Strategy Officer at
Carbon Health where he leads the omnichannel care model and the device-enabled
home care operations. Prior to joining Carbon Health in June 2021, he served as
Head of Health Strategic Initiatives at Apple from August 2015 to May 2021 where
he developed and led product initiatives and global strategic partnerships.
Earlier in his career, Mr. Cha was a Principal and Co-Leader of the West Coast
Strategy and Corporate Finance Practice as well as Co-Leader of the Healthcare
Investor Practice at McKinsey & Company. Mr. Cha holds a JD from Harvard Law
School
, an MBA from Harvard Business School and an AB in Biochemical Sciences
from Harvard College.

The Board believes Mr. Cha’s experience as a healthcare and consumer technology
executive developing and leading global and strategic initiatives and
partnerships, while maximizing the value of data and using analytics to drive
enhanced customer experiences and better clinical outcomes, brings to the Board
critical skills related to advancing the Company’s ecosystem of data-driven
products and services, which qualify him to serve as one of the Company’s
directors.

In Mr. Cha’s role as director and as a member of the Compensation Committee he
will be eligible to participate in the director compensation plans and
arrangements available to the Company’s other independent directors. The
Company’s director compensation program is described under the caption “Director
Compensation” in the Company’s proxy statement for its 2022 Annual Meeting of
Stockholders filed with the Securities and Exchange Commission on April 13,
2022
. In addition, Mr. Cha and the Company will enter into the Company’s
standard form indemnification agreement.

Other than the aforementioned items, there are no arrangements or understandings
between Mr. Cha and any other person pursuant to which Mr. Cha was elected as a
director. There are no family relationships between Mr. Cha and any director or
executive officer of the Company, and Mr. Cha has no direct or indirect material
interest in any “related party” transaction required to be disclosed pursuant to
Item 404(a) of Regulation S-K

(d) Appointment of Joao Malagueira as Director

Effective June 15, 2022, the Board increased the size of the Board from nine
directors to ten directors in accordance with the Company’s Amended and Restated
Bylaws, and elected Joao Malagueira, age 56, to serve as a Class I director on
the Board, with a term that expires at the Annual Meeting of Stockholders of the
Company to be held in 2023 or until his earlier resignation or removal. The
Board has approved Mr. Malagueira’s appointment to the Audit Committee. The
Board has affirmatively determined that Mr. Malagueira qualifies as an
“independent director” under the Nasdaq Listing Rules.

Mr. Malagueira brings more than 25 years of experience in diabetes, medical
devices and diagnostics solutions businesses with global corporations. Mr.
Malagueira is currently Vice President for three divisions at Hologic and
responsible for the entire portfolio in the EMEA. Prior to starting this role in
January 2019, he served as International Vice President, for EMEA and Canada,
for the Hologic Diagnostics Solutions division, from June 2015 to December 2018.
He possesses extensive experience and proven success of go-to-market models and
strategies in Europe, Africa, CIS, and the Middle East. Prior to Hologic, Mr.
Malagueira enjoyed more than 15 years in Johnson & Johnson, in commercial
leading roles across EMEA, where he led successful turnarounds and market share
growth of the diabetes solutions businesses, LifeScan and Animas. Mr. Malagueira
holds an MBA and an Advanced Degree in Marketing from Catolica Lisbon School of
Business and Economics
. He holds a MS in Pharmaceutical Sciences and Clinical
Analysis from University of Lisbon.


                                       2

——————————————————————————–

The Board believes Mr. Malagueira’s experience in diabetes and medical devices
across global organizations with extensive knowledge of international
go-to-market models and strategies brings to the Board critical skills related
to advancing the Company’s global reach and expansion of its global technology
offerings, which qualifies him to serve as one of the Company’s directors.

In Mr. Malagueira’s role as director and as a member of the Audit Committee he
will be eligible to participate in the director compensation plans and
arrangements available to the Company’s other independent directors. The
Company’s director compensation program is described under the caption “Director
Compensation” in the Company’s proxy statement for its 2022 Annual Meeting of
Stockholders filed with the Securities and Exchange Commission on April 13,
2022
. In addition, Mr. Malagueira and the Company will enter into the Company’s
standard form indemnification agreement.

Other than the aforementioned items, there are no arrangements or understandings
between Mr. Malagueira and any other person pursuant to which Mr. Malagueira was
elected as a director. There are no family relationships between Mr. Malagueira
and any director or executive officer of the Company, and Mr. Malagueira has no
direct or indirect material interest in any “related party” transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


   Number           Description
    99.1              Press release of Tandem Diabetes Care, Inc. dated June 16, 2022
     104            Cover Page Interactive Data File (embedded within the Inline XBRL document).





                                       3

——————————————————————————–

© Edgar Online, source Glimpses

Leave a Reply

Your email address will not be published.